Grant W Reed1, Mouin S Abdallah1, Mingyuan Shao2, Kathy Wolski2, Lisa Wisniewski2, Neville Yeomans3, Thomas F Lüscher4, Jeffrey S Borer5, David Y Graham6, M Elaine Husni7, Daniel H Solomon8, Peter Libby8, Venu Menon1, A Michael Lincoff1, Steven E Nissen9. 1. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio. 2. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio. 3. University of Melbourne Department of Medicine, Austin Health, Melbourne, Victoria, and Western Sydney University, Campbelltown, New South Wales, Australia. 4. Royal Brompton & Harefield Hospitals Trust and Imperial College, London, United Kingdom. 5. Schiavone Cardiovascular Translational Research Institute, State University of New York, Downstate Medical Center and College of Medicine, Brooklyn and New York, New York. 6. Baylor College of Medicine, Veterans Affairs Medical Center, Houston, Texas. 7. Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, Ohio. 8. Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 9. Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio. Electronic address: nissens@ccf.org.
Abstract
BACKGROUND: The safety of nonsteroidal anti-inflammatory drug (NSAID) and aspirin coadministration is uncertain. OBJECTIVES: The aim of this study was to compare the safety of combining NSAIDs with low-dose aspirin. METHODS: This analysis of the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen) trial included 23,953 patients with osteoarthritis or rheumatoid arthritis at increased cardiovascular risk randomized tocelecoxib, ibuprofen, or naproxen. The on-treatment population was used for this study. Outcomes included composite major adverse cardiovascular events, noncardiovascular death, gastrointestinal or renal events, and components of the composite. Cox proportional hazards models compared outcomes among NSAIDs stratified by aspirin use following propensity score adjustment. Kaplan-Meier analysis was used to compare the cumulative probability of events. RESULTS: When taken without aspirin, naproxen or ibuprofen had greater risk for the primary composite endpoint compared with celecoxib (hazard ratio [HR]: 1.52; 95% confidence interval [CI]: 1.22 to 1.90, p <0.001; and HR: 1.81; 95% CI: 1.46 to 2.26; p <0.001, respectively). Compared with celecoxib, ibuprofen had more major adverse cardiovascular events (p < 0.05), and both ibuprofen and naproxen had more gastrointestinal (p < 0.001) and renal (p < 0.05) events. Taken with aspirin, ibuprofen had greater risk for the primary composite endpoint compared with celecoxib (HR: 1.27; 95% CI: 1.06 to 1.51; p < 0.01); this was not significantly higher with naproxen (HR: 1.18; 95% CI: 0.98 to 1.41; p = 0.08). Among patients on aspirin, major adverse cardiovascular events were similar among NSAIDs, and compared with celecoxib, ibuprofen had more gastrointestinal and renal events (p < 0.05), while naproxen had more gastrointestinal events (p < 0.05), without a difference in renal events. Similar results were seen on adjusted Kaplan-Meier analysis. CONCLUSIONS:Celecoxib has a more favorable overall safety profile than naproxen or ibuprofen when taken without aspirin. Adding aspirin attenuates the safety advantage of celecoxib, although celecoxib is still associated with fewer gastrointestinal events than ibuprofen or naproxen and fewer renal events than ibuprofen. (Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen [PRECISION]; NCT00346216).
RCT Entities:
BACKGROUND: The safety of nonsteroidal anti-inflammatory drug (NSAID) and aspirin coadministration is uncertain. OBJECTIVES: The aim of this study was to compare the safety of combining NSAIDs with low-dose aspirin. METHODS: This analysis of the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen) trial included 23,953 patients with osteoarthritis or rheumatoid arthritis at increased cardiovascular risk randomized to celecoxib, ibuprofen, or naproxen. The on-treatment population was used for this study. Outcomes included composite major adverse cardiovascular events, noncardiovascular death, gastrointestinal or renal events, and components of the composite. Cox proportional hazards models compared outcomes among NSAIDs stratified by aspirin use following propensity score adjustment. Kaplan-Meier analysis was used to compare the cumulative probability of events. RESULTS: When taken without aspirin, naproxen or ibuprofen had greater risk for the primary composite endpoint compared with celecoxib (hazard ratio [HR]: 1.52; 95% confidence interval [CI]: 1.22 to 1.90, p <0.001; and HR: 1.81; 95% CI: 1.46 to 2.26; p <0.001, respectively). Compared with celecoxib, ibuprofen had more major adverse cardiovascular events (p < 0.05), and both ibuprofen and naproxen had more gastrointestinal (p < 0.001) and renal (p < 0.05) events. Taken with aspirin, ibuprofen had greater risk for the primary composite endpoint compared with celecoxib (HR: 1.27; 95% CI: 1.06 to 1.51; p < 0.01); this was not significantly higher with naproxen (HR: 1.18; 95% CI: 0.98 to 1.41; p = 0.08). Among patients on aspirin, major adverse cardiovascular events were similar among NSAIDs, and compared with celecoxib, ibuprofen had more gastrointestinal and renal events (p < 0.05), while naproxen had more gastrointestinal events (p < 0.05), without a difference in renal events. Similar results were seen on adjusted Kaplan-Meier analysis. CONCLUSIONS:Celecoxib has a more favorable overall safety profile than naproxen or ibuprofen when taken without aspirin. Adding aspirin attenuates the safety advantage of celecoxib, although celecoxib is still associated with fewer gastrointestinal events than ibuprofen or naproxen and fewer renal events than ibuprofen. (Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen [PRECISION]; NCT00346216).
Authors: Naveen L Pereira; Charanjit S Rihal; Derek Y F So; Yves Rosenberg; Ryan J Lennon; Verghese Mathew; Shaun G Goodman; Richard M Weinshilboum; Liewei Wang; Linnea M Baudhuin; Amir Lerman; Ahmed Hasan; Erin Iturriaga; Yi-Ping Fu; Nancy Geller; Kent Bailey; Michael E Farkouh Journal: Circ Cardiovasc Interv Date: 2019-04 Impact factor: 6.546
Authors: Massimiliano Ruscica; Alberto Corsini; Nicola Ferri; Maciej Banach; Cesare R Sirtori Journal: Pharmacol Res Date: 2020-05-20 Impact factor: 7.658
Authors: Alberto Magni; Piergiuseppe Agostoni; Cesare Bonezzi; Giuseppe Massazza; Paolo Menè; Vincenzo Savarino; Diego Fornasari Journal: Pain Ther Date: 2021-04-19
Authors: Kok Yuen Ho; Kok Ann Gwee; Yew Kuang Cheng; Kam Hon Yoon; Hwan Tak Hee; Abdul Razakjr Omar Journal: J Pain Res Date: 2018-09-20 Impact factor: 3.133